National Institute for Health and Clinical Excellence (NICE)
Health organisations working to incorporate NICE recommendations into NHS care to benefit thousands of patients who have had a stroke
An NHS workforce and resource impact statement published yesterday (17 July 2019) highlights the work being done by national partners to integrate changes recommended by NICE in its updated stroke guideline into routine NHS patient care.
The statement is the result of a collaboration between NICE, NHS England and NHS Improvement, NHS Clinical Commissioners, and Health Education England. It is designed to help commissioners and trusts understand the potential impact on the NHS workforce and resources of implementing specific NICE guidelines.
Stroke affects around 230 people per 100,000 each year, with over 80,000 people hospitalised per year in England. It is the single biggest cause of disability in adults, with an estimated annual cost to the NHS of £2.98 billion per year. A further £4.55 billion per year is estimated to be spent on social care for people who have had a stroke.
The workforce and resource impact statement estimates the costs to the NHS of increasing the provision of thrombectomy - a procedure to remove the blood clot causing the stroke - will be around £3.7 million in the first year, rising to £18.5 million in year 5. However, it is likely that these will be offset by cost savings for NHS and social care services of around £15.4 million in year 5 as a result of shorter hospital stays and reductions in future NHS supportive care and social care costs.
The potential increased costs of additional MRI requests for patients suspected of having a ‘mini-stroke’ – a transient ischaemic attack (TIA) - will be offset by savings gained through no longer routinely offering CT brain scanning to everyone with a suspected TIA. The net impact of these recommendations is estimated to be a cost saving of around £800,000 in year 5.
Overall, implementation of the guideline in England will cost around £18.6 million in 2023/24, although this will be offset by NHS and social care cost savings of around £16.2 million.
The statement also highlights the initiatives underway both within and across organisations to put the NICE guideline recommendations into practice, including support by NHS England specialised commissioning for the implementation of a thrombectomy service specification across the country. These initiatives will ensure the provision of the most effective, up-to-date treatments and in doing so will improve patient care.
Health Education England will work with the medical Royal Colleges and others to develop new training programmes for hospital consultants to offer mechanical thrombectomy.
In addition, the newly established Stroke Delivery Board (as part of the NHS Long Term Plan) includes a focus on increasing rates of thrombectomy, as well as improving the delivery of hyper-acute stroke pathways. Delivery and performance will be monitored and supported regionally by NHSE and the Getting it Right First Time (GIRFT) Stroke Programme.
The statement published yesterday was developed by a guideline resource and implementation (GRIP) panel, comprising members from NICE, Health Education England, NHS Clinical Commissioners, and NHS England and NHS Improvement.
The GRIP panel has been set up to focus on NICE guidelines that are most likely to have a substantial resource impact on the NHS - either where the total cost of implementing a guideline is likely to be more than £5 million per year, or where the cost of implementing a single recommendation within the guideline is likely to exceed £1 million per year.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Sir Andrew Dillon to stand down as NICE chief executive22/08/2019 12:15:00
Chief executive has been at the helm of the institute since it was founded in April 1999.
NICE draft guidance and NHS England review highlight need for more research on cannabis-based medicinal products08/08/2019 15:15:00
NICE has today (8 August 2019) published its draft recommendations on the use of cannabis-based medicinal products following a comprehensive evaluation of their clinical and cost-effectiveness
New lung cancer treatment option approved by NICE08/08/2019 12:15:00
Another new life-extending treatment for some people with lung cancer is to be made available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (8 August 2019).
NICE recommends additional treatment option for people with early breast cancer08/08/2019 09:15:00
NICE yesterday (7 August 2019) published a draft guidance recommending neratinib as an additional treatment for some people with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Unpaid carers need more support to cope with financial and emotional stress05/08/2019 11:15:00
NICE has published new draft guidance which aims to improve the wellbeing of adults who provide unpaid care for people over 16 years old.
Offer daily aspirin to those with inherited genetic condition to reduce the risk of colorectal cancer02/08/2019 14:15:00
Aspirin taken daily for 2 years or more could reduce the risk of colorectal cancer in people with Lynch syndrome (LS), says NICE in new draft updated guidance.
Improving service user experience in adult mental health services31/07/2019 16:15:00
Kathryn Mason, Head of Hospital Inspection (mental health), discusses the work CQC is undertaking to improve the quality and safety of mental health services
Innovative treatment for gynaecological cancers approved for Cancer Drugs Fund26/07/2019 13:15:00
Olaparib, a medicine that has previously been used at a later stage in the treatment of advanced ovarian cancer, has now been approved by NICE as a first-line maintenance treatment.
NICE, British Thoracic Society (BTS) and Scottish Intercollegiate Guideline Network (SIGN) to produce joint guideline on chronic asthma as part of broader 'asthma pathway'25/07/2019 12:15:00
NICE, BTS and SIGN yesterday (Wednesday 24 July) announced that future UK-wide guidance for the diagnosis and management of chronic asthma in adults, young people and children will be produced jointly by the three organisations.